Financings – Cont. from Vital Signs 11/7/23
Autumn leaves
Listings that didn’t get included in the 11/7/23 edition of Vital Signs are here.

If you are NOT receiving Vital Signs via email, send us a note and we’ll make sure to get you on the distribution list. The email briefing is designed to keep you informed of financings, new ideas and provide helpful educational links. It circulates during the week and typically twice a week unless there is a busy news cycle in which case it can circulate as often as daily. (vitalsigns at

Engine Biosciences – a developer of oncology medicines, raised a $27M Series A extension. (Singapore / Redwood City, CA)

Memo Therapeutics – a company developing therapeutics for viral infection and cancer patients, raised a $27.7M Series C. (Zurich, Switzerland)

Stellaromics – a developer of biotech products designed to advance 3D biologic analysis, raised a $25M Series A. (Boston, MA)

Recent Posts

Tax Strategies – QSBS

There are three things that create drag on investment returns: 1) Losses 2) Taxes 3)…

Financings – Cont. from Vital Signs 12/1/23

We had several financings that didnt make the 12/1 edition of Vital Signs. Biolexis Therapeutics…


When a startup or an investment is successful, it’s more likely that we attribute the…